Literature DB >> 32064084

The economic burden of metastatic breast cancer in Spain.

Begoña Bermejo de Las Heras1, Javier Cortes Ramon Y Cajal2, Elena Galve Calvo3, Juan de la Haba Rodriguez4,5, Jesus Garcia Mata6, Fernando Moreno Anton7, Ignacio Pelaez Fernandez8, Alvaro Rodriguez-Lescure9,10, Cesar A Rodriguez Sanchez11, Manuel Ruiz-Borrego12, Edit Remak13, Magdolna Barra13, Maria Rivero14, Javier Soto Alvarez14.   

Abstract

Objectives: The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.
Methods: An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.
Results: The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR-and €94,572 for triple negative patients over 5 years. Conclusions: The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  costs of illness; direct costs; metastatic breast cancer; resource utilisation; treatment patterns

Year:  2018        PMID： 32064084      PMCID： PMC6992969          DOI： 10.1136/ejhpharm-2017-001453

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN： 2047-9956


  13 in total

1.  Spanish recommendations on economic evaluation of health technologies.

Authors:  Julio López-Bastida; Juan Oliva; Fernando Antoñanzas; Anna García-Altés; Ramón Gisbert; Javier Mar; Jaume Puig-Junoy
Journal:  Eur J Health Econ       Date:  2010-04-20

2.  Incidence-based cost-of-illness model for metastatic breast cancer in the United States.

Authors:  Sonja V Sorensen; Jo Wern Goh; Feng Pan; Connie Chen; Denise Yardley; Miguel Martín; Kevin Knopf; Agnes Benedict; Carla Giorgetti; Shrividya Iyer
Journal:  Int J Technol Assess Health Care       Date:  2012-01       Impact factor: 2.188

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.

Authors:  Carmen Frías; Javier Cortés; Miguel Ángel Seguí; Itziar Oyagüez; Miguel Ángel Casado
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

5.  Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey.

Authors:  Mitch DeKoven; Vijayveer Bonthapally; Xiaolong Jiao; Arijit Ganguli; Prathamesh Pathak; Won Chan Lee; Saurabh Ray
Journal:  J Comp Eff Res       Date:  2012-09       Impact factor: 1.744

6.  Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.

Authors:  Dorien J A Lobbezoo; Roel J W van Kampen; Adri C Voogd; M Wouter Dercksen; Franchette van den Berkmortel; Tineke J Smilde; Agnes J van de Wouw; Frank P J Peters; Johanna M G H van Riel; Natascha A J B Peters; Maaike de Boer; George F Borm; Vivianne C G Tjan-Heijnen
Journal:  Breast Cancer Res Treat       Date:  2013-10-09       Impact factor: 4.872

7.  Economic burden of cancer across the European Union: a population-based cost analysis.

Authors:  Ramon Luengo-Fernandez; Jose Leal; Alastair Gray; Richard Sullivan
Journal:  Lancet Oncol       Date:  2013-10-14       Impact factor: 41.316

8.  Factors affecting 5- and 10-year survival of women with breast cancer: an analysis based on a public general hospital in Barcelona.

Authors:  Francesc Macià; Miquel Porta; Cristiane Murta-Nascimento; Sònia Servitja; Mònica Guxens; Andrea Burón; Ignasi Tusquets; Joan Albanell; Xavier Castells
Journal:  Cancer Epidemiol       Date:  2012-07-31       Impact factor: 2.984

9.  SEOM clinical guidelines in metastatic breast cancer 2015.

Authors:  J Gavilá; S Lopez-Tarruella; C Saura; M Muñoz; M Oliveira; L De la Cruz-Merino; S Morales; I Alvarez; J A Virizuela; M Martin
Journal:  Clin Transl Oncol       Date:  2015-12-18       Impact factor: 3.405

10.  Defining the optimal sequence for the systemic treatment of metastatic breast cancer.

Authors:  J A Mestres; A B iMolins; L C Martínez; J I C López-Muñiz; E C Gil; A de Juan Ferré; S Del Barco Berrón; Y F Pérez; J G Mata; A G Palomo; J G Gregori; P G Pardo; J J I Mañas; A L Hernández; E M de Dueñas; N M Jáñez; S M Murillo; J S Bofill; P Z Auñón; P Sanchez-Rovira
Journal:  Clin Transl Oncol       Date:  2016-06-17       Impact factor: 3.405
View more
  5 in total

1.  Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016.

Authors:  M Spanggaard; J Olsen; K F Jensen; M Anderson
Journal:  BMC Health Serv Res       Date:  2022-06-04       Impact factor: 2.908

2.  Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study.

Authors:  Katharina M D Merollini; Louisa G Gordon; Joanne F Aitken; Michael G Kimlin
Journal:  Int J Environ Res Public Health       Date:  2020-04-20       Impact factor: 3.390

3.  Cancer Survivors' Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q).

Authors:  Katharina M D Merollini; Louisa G Gordon; Yiu M Ho; Joanne F Aitken; Michael G Kimlin
Journal:  Int J Environ Res Public Health       Date:  2022-08-02       Impact factor: 4.614

4.  Hospitalization and ambulatory costs related to breast cancer due to physical inactivity in the Brazilian state capitals.

Authors:  Diego Augusto Santos Silva
Journal:  PLoS One       Date:  2022-01-19       Impact factor: 3.240

5.  Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.

Authors:  Min Huang; Amin Haiderali; Grace E Fox; Andrew Frederickson; Javier Cortes; Peter A Fasching; Joyce O'Shaughnessy
Journal:  Pharmacoeconomics       Date:  2022-02-03       Impact factor: 4.558
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.